GenSpera combines its novel biomedical technology platform with powerful insight and rigorous scientific methods to develop targeted treatments with fewer side-effects Phase II clinical trials for lead compound for mipsagargin, also known as G-202, are underway in two indications: Hepatocellular carcinoma, or liver cancer Glioblastoma, or brain cancer Experienced and motivated team drives the process: Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and founders Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen: Strong intellectual property portfolio No milestones or royalty payments owed to third parties Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic

Publications show all

GenSpera has published 1 articles.

Patents show all

31Applications17Issued

Clinical Trials show all

6Phase 21N/A1Phase 1

SEC Filings show all

8-K11110-Q26D1610-K9S-11

Contact Information


    SEC Form D Funding Events

    DateOfferedSoldType
    2014-12-09$280,000$280,000Equity
    2014-06-30$2,000,000$773,000Equity, Option to Acquire
    2013-09-10$20,000,000$5,000,032Equity, Option to Acquire
    2013-04-05$6,000,000$1,869,000Equity, Option to Acquire
    2011-05-24$3,500,000$2,249,750Equity, Option to Acquire, Other
    2011-03-14$4,145,578$4,145,578Equity, Option to Acquire, Other
    2010-06-21$2,695,000$2,695,000Equity, Option to Acquire, Other
    2009-09-18$250,000$240,000Equity, Option to Acquire, Other
    2009-08-03$3,038,000$3,038,000Equity, Option to Acquire, Other
    2009-07-08$4,000,000$750,000Equity, Option to Acquire, Other
    2009-07-07$4,000,000$2,320,000Equity, Option to Acquire, Other
    2007-12-12UnknownUnknownOther (Paper Filing)

    Key Executives

    • Craig Dionne
      Director, Executive Officer
    • John M Farah
      Director
    • Scott Ogilvie
      Director
    • John Farah
      Director
    • Scott Oglive
      Director
    • John M. Farah
      Director
    • Russell Richerson
      Executive Officer
    • Scott V. Ogilvie
      Director
    • Bo Jesper Hansen
      Director
    • Scott V Ogilvie
      Director
    • Peter Grebow
      Director
    • Nancy Jean Barnabei
      Executive Officer